Hemoglobinopathies Market, By Type (Sickle Cell Disease and Thalassemia), By Therapy (ACE inhibitors, Monoclonal Antibody Medication and Hydroxyurea), By Distribution Channel (Online Providers, Hospital Pharmacy, Drug Stores and Retail Pharmacy), By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
REPORT HIGHLIGHT
Hemoglobinopathies Market size was valued at USD 8,428 Million in 2023, expanding at a CAGR of 12.5% from 2024 to 2032.
Hemoglobinopathy diagnosis and treatment are becoming more and more common due to the growing demand for newborn screening programs and the diagnosis of prenatal hemoglobin abnormalities. This is particularly critical in poorer countries where screening and awareness initiatives are only getting underway. Additionally, it is anticipated that growing patient and healthcare professional awareness of the need for early diagnosis and treatment will propel market revenue growth. This is particularly true in the case of sickle cell anemia when early detection and treatment can significantly improve patient outcomes and reduce healthcare costs. However, a significant factor that can limit market revenue development is the high cost of treatment, particularly for gene therapy and stem cell transplants. Moreover, severe legislative limitations, and a lack of access to healthcare in developing countries, especially for those in need of specialized treatment, are increasing the prevalence of hemoglobinopathies worldwide.
Hemoglobinopathies Market- Market Dynamics
- Increasing prevalence of hemoglobinopathies in developing and low-income countries boosting the market growth
Haemoglobinopathies, including sickle cell disease and Thalassemia, are hereditary conditions that can be prevented. In their severe forms, they are linked to chronic, life-threatening, and life-impairing diseases with substantial health risks that can result in death or disability. Unfortunately, due to a lack of knowledge, comprehensive programs, and organized preventative measures, a significant percentage of children worldwide are born with and suffer from these conditions. According to BGI Genomics Global 2023, 5.2% of people worldwide have hemoglobin abnormalities, which causes 300,000 to 400,000 babies to be born with severe hemoglobinopathies every year. In addition, 4.4 out of every 10,000 live births is affected with thalassemia, a hereditary hemoglobinopathy that is most common in Mediterranean coastal regions, Africa, the Middle East, Southeast Asia, and southern China. Roughly 80% of cases of thalassemia take place in low- and middle-income nations, where patients\' quality of life is more likely to be in danger due to unequal access to medical care. Programs to control thalassemia must include genetic counselling, screening, public awareness, and prenatal diagnosis. Considering the magnitude of the problem and the cost implications of management, suitable control measures need to be undertaken immediately.
Hemoglobinopathies Market- Key Insights
- As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.5% over the forecast period (2024-2032)
- Based on type segmentation, the Sickle Cell Disease segment is expected to dominate the market over the forecast period
- Based on region, North America is expected to dominate the market during the forecast period
Hemoglobinopathies Market- Segmentation Analysis:
The Global Hemoglobinopathies Market is segmented based on Type, Therapy, Distribution Channel, and Region.
Based on the type, the global market is categorized into Sickle Cell Disease, Thalassemia and Others. The Sickle Cell Disease segment is expected to dominate the market over the forecast period. The market for sickle cell disease diagnostics has seen several notable developments recently. The creation and uptake of novel diagnostic technology is one such trend. Modern genetic testing techniques, including next-generation sequencing and molecular diagnostics, have made it possible to identify sickle cell disease and its variations more precisely and effectively. Rapid diagnostic kits and point-of-care testing (POCT) equipment have also been developed, making screening quick and easy in a variety of healthcare settings. For instance, Molbio Diagnostics and ShanMukha Innovations partnered in May 2023 to create, develop, and market affordable point-of-care diagnostic tools for the diagnosis of disorders associated with hemoglobinopathy.
Based on the therapy, the global hemoglobinopathies industry is divided into ACE inhibitors, Monoclonal Antibody Medication, Hydroxyurea and Others.
Based on the distribution channel, the market is bifurcated into Online Providers, Hospital Pharmacy, Drug Stores and Retail Pharmacy.
Hemoglobinopathies Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period because healthcare facilities are getting better and individuals are becoming more aware of hemoglobinopathies. Different groups run different activities to raise awareness. For instance, the United States national group SCDAA advocates for people with sickle cell disease and their families by raising awareness and providing support. To foster greater awareness and enhance the lives of individuals who suffer from the disease, they arrange events, offer resources, and give instructional materials. The region\'s market is expected to rise as a result of several programs launched by government agencies and research institutions to support the development of new treatments for hemoglobinopathies.
Hemoglobinopathies Market- Competitive Landscape:
To increase their market share, business leaders are launching several efforts, including partnerships, collaborations, mergers and acquisitions, and intensive R&D. The key players operating in the market are Novartis AG, Celgene Corporation, bluebird bio, Inc., Emmaus Life Sciences Inc., Pfizer, Inc., Sangamo Therapeutics, Inc., Prolong Pharmaceuticals, LLC, Global Blood Therapeutics, Inc., Gamida Cell and Bioverativ Inc.
Recent Developments:
- In August 2023, the FDA in the United States released the clinical hold on the Investigational New Drug (IND) application for FTX-6058, which could be used to treat sickle-cell disease (SCD). Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that prioritizes improving the lives of patients with genetically defined rare diseases.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL HEMOGLOBINOPATHIES MARKET KEY PLAYERS
- Novartis AG
- Celgene Corporation
- bluebird bio, Inc.
- Emmaus Life Sciences Inc.
- Pfizer, Inc.
- Sangamo Therapeutics, Inc.
- Prolong Pharmaceuticals, LLC
- Global Blood Therapeutics, Inc.
- Gamida Cell
- Bioverativ Inc.
GLOBAL HEMOGLOBINOPATHIES MARKET, BY TYPE
- Sickle Cell Disease
- Thalassemia
- Others
GLOBAL HEMOGLOBINOPATHIES MARKET, BY THERAPY
- ACE inhibitors
- Monoclonal Antibody Medication
- Hydroxyurea
- Others
GLOBAL HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL
- Online Providers
- Hospital Pharmacy
- Drug Stores
- Retail Pharmacy
GLOBAL HEMOGLOBINOPATHIES MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Hemoglobinopathies Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Hemoglobinopathies Market Snippet by Type
2.1.2. Hemoglobinopathies Market Snippet by Therapy
2.1.3. Hemoglobinopathies Market Snippet by Distribution Channel
2.1.4. Hemoglobinopathies Market Snippet by Country
2.1.5. Hemoglobinopathies Market Snippet by Region
2.2. Competitive Insights
3. Hemoglobinopathies Key Market Trends
3.1. Hemoglobinopathies Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Hemoglobinopathies Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Hemoglobinopathies Market Opportunities
3.4. Hemoglobinopathies Market Future Trends
4. Hemoglobinopathies Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Hemoglobinopathies Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Hemoglobinopathies Market Landscape
6.1. Hemoglobinopathies Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Hemoglobinopathies Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
7.1.2. Sickle Cell Disease
7.1.3. Thalassemia
7.1.4. Others
8. Hemoglobinopathies Market – By Therapy
8.1. Overview
8.1.1. Segment Share Analysis, By Therapy, 2023 & 2032 (%)
8.1.2. ACE inhibitors
8.1.3. Monoclonal Antibody Medication
8.1.4. Hydroxyurea
8.1.5. Others
9. Hemoglobinopathies Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
9.1.2. Online Providers
9.1.3. Hospital Pharmacy
9.1.4. Drug Stores
9.1.5. Retail Pharmacy
10. Hemoglobinopathies Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Hemoglobinopathies Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Hemoglobinopathies Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Hemoglobinopathies Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Hemoglobinopathies Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Hemoglobinopathies Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Therapy, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Hemoglobinopathies Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Novartis AG
11.2.2. Celgene Corporation
11.2.3. bluebird bio, Inc.
11.2.4. Emmaus Life Sciences Inc.
11.2.5. Pfizer, Inc.
11.2.6. Sangamo Therapeutics, Inc.
11.2.7. Prolong Pharmaceuticals, LLC
11.2.8. Global Blood Therapeutics, Inc.
11.2.9. Gamida Cell
11.2.10. Bioverativ Inc.
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
